Biotech »

ProMetic receives $5.6-million order from Octapharma

ProMetic receives $5.6-million order from Octapharma

Alpha Stox June 5, 2014 Comments Off

Mr. Pierre Laurin reports PROMETIC RECEIVES A $5.6 MILLION PURCHASE ORDER FROM OCTAPHARMA ProMetic Life Sciences Inc. has received a $5.6-million purchase order under its continuing supply agreement with Octapharma, a leading, Swiss, independent,

Read More »
Sirona licensee starts preclinical validation for drug

Sirona licensee starts preclinical validation for drug

Alpha Stox June 3, 2014 Comments Off

An anonymous director reports SIRONA BIOCHEM ANNOUNCES WANBANG BIOPHARMACEUTICAL’S LAUNCH OF PRE-CLINICAL VALIDATION Sirona Biochem Corp. licensee Wanbang Biopharmaceuticals has begun preclinical validation for Sirona Biochem’s second-generation SGLT2 inhibitor. To date, Sirona has received

Read More »
Sirona Biochem Expands Exclusive Skin Lightening License with Valeant Pharmaceuticals to Include AMBI and Kinerase

Sirona Biochem Expands Exclusive Skin Lightening License with Valeant Pharmaceuticals to Include AMBI and Kinerase

Alpha Stox May 29, 2014 Comments Off

Vancouver, British Columbia – May 29, 2014 – Sirona Biochem Corp. (TSX-V: SBM.V) (OTCQX: SRBCF) (FRANKFURT: ZSB) announces the expansion of its exclusive license with Valeant Pharmaceuticals (“Valeant”) for Sirona’s skin lightening compound TFC-849

Read More »
Sirona Biochem’s TFC-837 can extend cell life

Sirona Biochem’s TFC-837 can extend cell life

Alpha Stox May 23, 2014 Comments Off

Mr. Neil Belenkie reports SIRONA BIOCHEM’S ANTI-AGING GLYCOPROTEIN SUCCESSFULLY EXTENDS CELL LIFE IN SERUM DEPRIVATION STUDY Sirona Biochem Corp.’s anti-aging compound TFC-837 was proven to extend cell life with outstanding results in a 12-day

Read More »
SQI Diagnostics loses $956,000 in fiscal Q2

SQI Diagnostics loses $956,000 in fiscal Q2

Alpha Stox May 12, 2014 Comments Off

Mr. Andrew Morris reports SQI RECORDS FIRST REVENUES FROM SALES TO GLOBAL PHARMACEUTICAL CUSTOMERS SQI Diagnostics Inc. has released its financial and operational results for its fiscal second quarter ended March 31, 2014. “This

Read More »
ProMetic Life increases NantPro interest to 60%

ProMetic Life increases NantPro interest to 60%

Alpha Stox May 9, 2014 Comments Off

Mr. Pierre Laurin reports PROMETIC INCREASES ITS OWNERSHIP STAKE IN NANTPRO BIOSCIENCES, LLC (“NANTPRO”) ProMetic Life Sciences Inc. has increased its ownership in NantPro Biosciences LLC following the amendment of its related corporate and

Read More »
Bellus, Auven enter licence agreement for Kiacta

Bellus, Auven enter licence agreement for Kiacta

Alpha Stox May 2, 2014 Comments Off

Ms. Kathy Armstrong of Auven reports AUVEN THERAPEUTICS AND BELLUS HEALTH ANNOUNCE LICENCE AGREEMENT WITH MOUNT SINAI FOR KIACTA(TM) IN SARCOIDOSIS Auven Therapeutics and Bellus Health Inc. have entered into a licence agreement with

Read More »
Charles Duncan: 2014 Is for Careful Stock Pickers, Not Dart Throwers

Charles Duncan: 2014 Is for Careful Stock Pickers, Not Dart Throwers

Alpha Stox April 29, 2014 Comments Off

Source: George S. Mack of The Life Sciences Report (4/24/14) Charles Duncan Veteran Senior Biotechnology Analyst Charles Duncan of Piper Jaffray & Co. sees platform companies as the perfect way to play a consolidating

Read More »
Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases

Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases

Alpha Stox April 29, 2014 Comments Off

Source: George S. Mack of The Life Sciences Report (4/22/14) To cast a spotlight on disruptive biotechnology stocks, Raghuram “Ram” Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator

Read More »
Newsletterpopup_top_1

Your Name (required)

Your Email (required)

captcha

Newsletterpopup_bottom_1